SHPH — Shuttle Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$3.52
-$0.09 (-2.63%)
Shuttle Pharmaceuticals Inc (SHPH) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Christopher Robert Cooper BBA, M.B.A., MBA, based in 401 Professional Drive, Gaithersburg, MD, United States, 20879, with about 9 employees. Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Net income was -$9.1M. SHPH currently screens at market cap $1.8M.
On the latest cached filing, SHPH: AND EXCHANGE COMMISSION (8-K 2026-09-01). This SHPH stock page is the analysis view: what changed in the numbers, and why it matters for Shuttle Pharmaceuticals Inc.
Use this SHPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SHPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SHPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Shuttle Pharmaceuticals Inc even when a live quote feed is slow.
What changed in SHPH
8-K · 2026-09-01
SHPH: AND EXCHANGE COMMISSION
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
SHPH Key Statistics
Market Cap
$1.80M
Volume
11,956
Previous Close
$3.52
Day Range
$3.29 – $3.54
EPS
-$3.30
Revenue
$0.00
Net Income
-$9.54M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
9
SHPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.54M | -$6.59M | $1.69M | -$1.15M |
| EPS (Diluted) | -$3.30 | -$3.53 | -$0.29 | $0.00 |
Total Assets
$2.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.92M
Operating Cash Flow
-$7.33M
Free Cash Flow
$0.00
Shuttle Pharmaceuticals Inc Company Information
- Interim Chief Executive Officer
- Christopher Robert Cooper BBA, M.B.A., MBA
- Headquarters
- 401 Professional Drive, Gaithersburg, MD, United States, 20879
- Website
- www.shuttlepharma.com
- Phone
- 240 403 4212
- IPO / Founded
- 2022-08-31
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic